Literature DB >> 15015605

Polo-like kinase 1 (PLK1) expression is associated with cell proliferative activity and cdc2 expression in malignant lymphoma of the thyroid.

Yasuhiro Ito1, Hiroshi Yoshida, Fumio Matsuzuka, Nariaki Matsuura, Yasushi Nakamura, Hirokazu Nakamine, Kennichi Kakudo, Kanji Kuma, Akira Miyauchi.   

Abstract

BACKGROUND: Polo-like kinase 1 (PLK1) is one of the serine threonine kinases that plays a role in cellular proliferation by activating the CDC25C-CDK1 (cdc2) loop. We recently demonstrated that cdc2 expression is associated with the biological aggressiveness of malignant lymphoma of the thyroid. In this study, we investigated PLK1 expression in thyroid lymphoma in order to elucidate its physiological significance in this disease.
MATERIALS AND METHODS: We immunohistochemically investigated PLK1 expression in 46 cases of thyroid lymphoma and 10 cases of chronic thyroiditis.
RESULTS: Normal follicular cells did not express PLK1, whereas follicular cells in those in chronic thyroiditis and malignant lymphoma demonstrated a high level of PLK1 expression. In lymphocytes in chronic thyroiditis with strong lymphocyte infiltration, PLK1 was weakly expressed. In malignant lymphoma, PLK1 expression was observed in all cases, but PLK1 was more strongly expressed in cases with high cell proliferative activity and with cdc2 expression.
CONCLUSION: These results suggest that PLK1 regulates the cell cycle progression of thyroid lymphoma cells in the G2-M-phase.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15015605

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  Calcium-dependent inhibition of polo-like kinase 3 activity by CIB1 in breast cancer cells.

Authors:  Meghna U Naik; Ngoc T Pham; Kristin Beebe; Wei Dai; Ulhas P Naik
Journal:  Int J Cancer       Date:  2011-02-01       Impact factor: 7.396

2.  Plk1 promotes the migration of human lung adenocarcinoma epithelial cells via STAT3 signaling.

Authors:  Weijuan Yan; Huijie Yu; Wei Li; Fengsheng Li; Sinian Wang; Nan Yu; Qisheng Jiang
Journal:  Oncol Lett       Date:  2018-09-14       Impact factor: 2.967

3.  Inhibitory effect of Polo-like kinase 1 depletion on mitosis and apoptosis of gastric cancer cells.

Authors:  Xue-Hua Chen; Bin Lan; Ying Qu; Xiao-Qing Zhang; Qu Cai; Bing-Ya Liu; Zheng-Gang Zhu
Journal:  World J Gastroenterol       Date:  2006-01-07       Impact factor: 5.742

Review 4.  Prediction of Genes Involved in Lung Cancer with a Systems Biology Approach Based on Comprehensive Gene Information.

Authors:  Shahram Parvin; Hamid Sedighian; Ehsan Sohrabi; Mahdieh Mahboobi; Milad Rezaei; Dariush Ghasemi; Ehsan Rezaei
Journal:  Biochem Genet       Date:  2021-12-02       Impact factor: 2.220

5.  Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells.

Authors:  Ding-pei Han; Qian-lin Zhu; Jiang-tao Cui; Pu-xiongzhi Wang; Shun Qu; Qi-feng Cao; Ya-ping Zong; Bo Feng; Min-hua Zheng; Ai-guo Lu
Journal:  Med Sci Monit       Date:  2012-06

6.  Depletion of mRNA export regulator DBP5/DDX19, GLE1 or IPPK that is a key enzyme for the production of IP6, resulting in differentially altered cytoplasmic mRNA expression and specific cell defect.

Authors:  Masumi Okamura; Yasutaka Yamanaka; Maki Shigemoto; Yuya Kitadani; Yuhko Kobayashi; Taiho Kambe; Masaya Nagao; Issei Kobayashi; Katsuzumi Okumura; Seiji Masuda
Journal:  PLoS One       Date:  2018-05-10       Impact factor: 3.240

Review 7.  Modelling the Functions of Polo-Like Kinases in Mice and Their Applications as Cancer Targets with a Special Focus on Ovarian Cancer.

Authors:  Monika Kressin; Daniela Fietz; Sven Becker; Klaus Strebhardt
Journal:  Cells       Date:  2021-05-12       Impact factor: 6.600

Review 8.  The Role of Primary Cilia in Thyroid Cancer: From Basic Research to Clinical Applications.

Authors:  Cheng-Xu Ma; Xiao-Ni Ma; Ying-Dong Li; Song-Bo Fu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-08       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.